AvenCell

An additional shoutout to Babar Ghias, Andrea Kistner and Jan Pape in the FP&A group at AvenCell for all the hard work in getting the financing across the line!

Thank you to Nasdaq for featuring AvenCell’s successful $112 million Series B financing on its iconic billboard in Times Square. We’re thrilled to partner with global life sciences investor Novo Holdings as we continue to advance our pipeline products through preclinical and clinical development, all with the goal of transforming the immunotherapy landscape and delivering better treatment options to patients with difficult to treat cancers and autoimmune diseases.

We are thrilled to announce that AvenCell has secured $112 million in Series B financing, led by global life sciences investor @Novo Holdings. This latest funding will accelerate clinical validation of our proprietary Universal Switchable CAR-T cell therapy platform, which was developed to more safely and effectively treat a wide range of hematologic malignancies and auto-immune diseases, and ultimately transform outcomes for patients around the world. Read the full announcement here: https://lnkd.in/eivannxn

🌈 Celebrating Pride Month at AvenCell! 🌈 At AvenCell, we believe that diversity and inclusion are essential to driving innovation and creating a better world. This Pride Month, we stand in solidarity with the LGBTQIA+ community and celebrate the invaluable contributions of our LGBTQIA+ colleagues, partners, and allies. Our commitment to an inclusive workplace where everyone feels valued and respected is undeviating. We fully recognize that promoting and empowering diversity in all its forms enriches our company culture, enhances our creativity and strengthens our ability to solve complex biotechnology challenges. We invite all of our employees, partners and community members to join us in this celebration and continue to champion equality and inclusion every day. Happy Pride Month! 🏳️🌈

Join us in celebrating the incredible achievements of women worldwide this International Women's Day!   At AvenCell, we're proud to recognize the diverse talents and unwavering dedication of women in shaping the future of technology and beyond. From pioneering innovations to leading teams with grace and resilience, their impact knows no bounds. Today, we reaffirm our commitment to fostering an inclusive and empowering environment where everyone, regardless of gender, can thrive and succeed. By embracing diversity and championing equality, we not only unlock the full potential of our team but also drive meaningful change in our industry and society.   To all the inspiring women within our company and beyond, thank you for your courage, passion, and relentless pursuit of excellence. Your contributions inspire us every day and remind us of the importance of amplifying diverse voices and perspectives.   Happy International Women's Day! Let's continue to #BreakTheBias, #EmpowerWomen, and build a brighter, more inclusive future together. #IWD2024 #WomenInTech #Innovation #Equality

We are excited to build on the safety and promising activity observed in our ongoing autologous switchable clinical study in AML (AVC-101) by now clinically implementing what we believe is the most scientifically compelling allogeneic technology in the industry in our AVC-201 study. https://lnkd.in/esqDj2Zr

AvenCell is pleased to announce that expanded clinical safety and efficacy data from its leading Universal Switchable CAR T Cell (“UniCAR”) Therapy program and preclinical data from its Switchable Allogeneic CAR platform will be revealed in poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition on December 09-12, 2023, in San Diego, California. https://lnkd.in/eB5KeWPX